LeMaitre Vascular (LMAT) Projected to Post Quarterly Earnings on Tuesday

LeMaitre Vascular (NASDAQ:LMAT) is expected to issue its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of $0.66 per share and revenue of $66.6740 million for the quarter. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 5:00 PM ET.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.67 by $0.01. The business had revenue of $64.45 million during the quarter, compared to analysts’ expectations of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.LeMaitre Vascular’s revenue was up 15.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.49 earnings per share. On average, analysts expect LeMaitre Vascular to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $110.11 on Monday. LeMaitre Vascular has a fifty-two week low of $78.01 and a fifty-two week high of $118.01. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. The company has a market capitalization of $2.52 billion, a price-to-earnings ratio of 43.87, a P/E/G ratio of 3.23 and a beta of 0.60. The business’s 50-day moving average is $108.90 and its 200-day moving average is $93.99.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Thursday, March 12th were given a dividend of $0.25 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, March 12th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 39.84%.

Insider Activity at LeMaitre Vascular

In other news, Director David B. Roberts sold 8,464 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares of the company’s stock, valued at $1,920,157.20. This represents a 32.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $106.76, for a total value of $16,014,000.00. Following the completion of the transaction, the chief executive officer owned 1,532,304 shares in the company, valued at $163,588,775.04. This represents a 8.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 215,438 shares of company stock valued at $23,062,911. 9.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dundas Partners LLP raised its holdings in shares of LeMaitre Vascular by 22.0% in the 4th quarter. Dundas Partners LLP now owns 3,246 shares of the medical instruments supplier’s stock worth $263,000 after purchasing an additional 586 shares during the period. NewEdge Advisors LLC raised its stake in shares of LeMaitre Vascular by 4.6% in the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after buying an additional 139 shares during the period. Jump Financial LLC purchased a new position in shares of LeMaitre Vascular during the 2nd quarter valued at $241,000. nVerses Capital LLC bought a new position in shares of LeMaitre Vascular during the 4th quarter worth $234,000. Finally, Virtu Financial LLC purchased a new stake in LeMaitre Vascular in the 3rd quarter worth about $216,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on LMAT shares. Wells Fargo & Company raised their price target on LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Citizens Jmp increased their price target on LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings raised LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and a consensus price target of $105.80.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.